CING

Cingulate Inc. Common Stock (CING)

Stock · NASDAQ · Health Care

$4.38as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 13, 2026

CING noted among health-care stocks with pre-market movement. CING was included in a Benzinga list of twelve health-care stocks that showed activity in the pre-market session on Tuesday. The mention suggests some early-day interest in the stock. The shares are currently near a support level of $5.03 and the RSI of 42.2 indicates modest momentum.

Active signals

Resistance level
$5.03
Industry
Biotechnology: Pharmaceutical Preparations

What CING's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike26+0.2%50%
Bollinger Band BreakdownActive now21+3.1%52%
Bollinger Band Breakout19-14.4%16%
200-Day Moving Average TouchActive now9+0.8%56%
Any 20-session window (baseline)-4.5%41%

Computed by MarketWall from daily closing prices since September 23, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About CING

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
14

Fundamentals

1-day range
$4.32$4.58
Market cap
$68.02M
P/E (trailing)
—
P/E (forward)
-4.91
EPS (trailing)
$-3.68
Dividend yield
—
Beta
-0.89
Avg. volume
124.8K
52-week range
$3.16$11.89

Forecasts

5 analyst ratings

Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$44
+904.6%
Median
$20
+356.6%
Low
$8
+82.6%

Cingulate Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • CING
    Cingulate Inc. Common Stock
    $4.36
    ▼ 0.68%
    Market cap $68.02MP/E —
    $3.16$11.89
  • CLNN
    Clene Inc. Common Stock
    $3.1
    ▼ 6.34%
    Market cap $68.24MP/E —
    $3.24$13.5
  • RNTX
    Rein Therapeutics Inc. Common Stock
    $0.59
    ▼ 6.05%
    Market cap $67.45MP/E —
    $0.5401$2.18
  • IBIO
    iBio Inc. Common Stock
    $0.77
    ▼ 1.28%
    Market cap $69.05MP/E —
    $0.7328$3.82
  • MNOV
    Medicinova Inc Common Stock
    $1.42
    ▼ 2.07%
    Market cap $66.94MP/E —
    $1.17$3.9
  • XBIT
    XBiotech Inc. Common Stock
    $2.12
    ▼ 1.85%
    Market cap $69.51MP/E —
    $2.09$3.44
  • INO
    Inovio Pharmaceuticals Inc. Common Stock
    $0.99
    ▼ 4.81%
    Market cap $69.62MP/E —
    $0.5632$2.72

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
683.2K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
1.13M
Total value held
$6.65M
Institutional holders
25
Top holders this quarter
  • Unknown309.0K
  • Unknown140.0K
  • Unknown101.4K
  • Unknown92.9K
  • Unknown90.9K
  • Unknown53.5K
  • Unknown51.2K
  • Unknown34.8K
  • Unknown33.1K
  • Unknown31.9K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.